Pharmaceutical Executive, April 2020 Issue (PDF)

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-04-01-2020
Volume 40
Issue 4

Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.

.

External Link - Pharm Exec_April 2020.pdf

Download Issue PDF
Articles in this issue
HBA's Woman of the Year 2020: A Motivated Mission
HBA's Woman of the Year 2020: A Motivated Mission
Doubling Down on D&I
Doubling Down on D&I
Lisa Henderson thumbnail.jpg
COVID-19 Ripple Effects for Pharma
Dan Wetherill.jpg
Prescribing Patterns: How to Get Ahead of the Trends
Globla Report PQ.png
There’s No Easing the Price-vs.-Value Debate
Gene fig 4.png
Payer Perspectives on Gene Therapy Reimbursement
Wash Report side.png
Covid-19 Pandemic Thrusts Biopharma R&D to Forefront
Transforming the CIO Role to Embrace Digital Health
Pharmaceutical Executive, April 2020 Issue (PDF)
Country Report: The Czech Republic
Recent Videos
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
Satish Shenoy

Generative AI and Digital Workers: Accelerating Innovation in the Pharma Industry

Satish Shenoy
March 31st 2025
Article

If used properly, AI can be a game-changer for drug development.

Peter Ax, UpScriptHealth

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Miranda Schmalfuhs
March 24th 2025
Podcast

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

FDA Approves AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer

FDA Approves AstraZeneca’s Imfinzi for Muscle-Invasive Bladder Cancer

Don Tracy, Associate Editor
March 31st 2025
Article

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.

Jennifer Butler

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
March 11th 2025
Podcast

Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.

Pharma Pulse 3/31/25: The Impact of Funding Cuts on Medical Research, Training Pharmacy Technicians as Community Health Workers & more

Pharma Pulse 3/31/25: The Impact of Funding Cuts on Medical Research, Training Pharmacy Technicians as Community Health Workers & more

Miranda Schmalfuhs
March 31st 2025
Article

The latest news for pharma industry insiders.

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC

Don Tracy, Associate Editor
March 31st 2025
Article

Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% compared to standard care in patients with epidermal growth factor receptor-mutated non-small cell lung cancer.